GlassScriptPhysician profile
James Matthew Andry
NPI 1447255369
$714,969.14
in general payments reported to CMS, 2019-2025
46 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $93K · 2021: $95K · 2022: $158K · 2023: $106K · 2024: $89K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $208K · Travel and Lodging: $43K · Food and Beverage: $7,796 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $207,905.49 |
| Travel and Lodging | $42,564.87 |
| Food and Beverage | $7,796.11 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $391,092.19 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $227,192.83 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $89,986.61 | 2019-2025 | Repatha, Repatha, Otezla |
| Eli Lilly and Company | $2,275.00 | 2021 | |
| Abbvie INC. | $960.01 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Astrazeneca Pharmaceuticals LP | $650.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Corcept Therapeutics | $401.46 | 2023-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.56 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $170.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $143.01 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.29 | 2022 | |
| Ironshore Pharmaceuticals INC. | $119.87 | 2022-2024 | Jornay Pm |
| Abbott Laboratories | $110.16 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $108.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.90 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Andry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.